作者
Majid Marjani, Payam Tabarsi, Afshin Moniri, Seyed Mohammadreza Hashemian, Seyed Alireza Nadji, Zahra Abtahian, Majid Malekmohammad, Arda Kiani, Behrooz Farzanegan, Alireza Eslaminejad, Atefeh Fakharian, Jalal Heshmatnia, Atefeh Abedini, Sharareh Seifi, Fatemeh Yassari, Maryam Sadat Mirenayat, Mitra Rezaei, Hakimeh Sheikhzade, Zargham Hossein Ahmadi, Farzaneh Dastan, Mohsen Sadeghi, Somayeh Lookzadeh, Mihan Porabdollah, Elham Askari, Parvaneh Baghaei, Babak Mansourafshar, Alireza Jahangirifard, Maryam Vasheghani, Mojtaba Mokhber Dezfuli, Mohammad Varahram, Hamidreza Jamaati, Davood Mansouri, Alireza Zali, Ali Akbar Velayati
发表日期
2020/11
来源
Tanaffos
卷号
19
期号
2
页码范围
91
出版商
National Research Institute of Tuberculosis and Lung Disease
简介
By 28 May 2020, the total number of laboratoryconfirmed cases of COVID-19 surpassed 5,701,337, with 357,688 reported deaths worldwide (2). Iran reported its first confirmed cases of COVID-19 on the 19 February 2020 in Qom, Qom Province (3), and by 29 May 2020, a total of 143,849 confirmed cases and 7627 deaths were reported (2). More than 300 active clinical trials concerning agents and therapeutic measures potentiality effective in the treatment of COVID-19 are underway. However, no proven effective therapies for this virus are supported by any currently existing randomized clinical trials (RCTs)(4).
学术搜索中的文章
M Marjani, P Tabarsi, A Moniri, SM Hashemian… - Tanaffos, 2020